ONCONETIX INC (ONCO) Stock Price, Quote, News and Overview
NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD
ONCO Quote, Performance and Key Statistics
4.12
+0.09 (+2.23%)
The current stock price of ONCO is 4.12 USD. In the past month the price decreased by -33.14%. In the past year, price decreased by -71.01%.
ONCO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 327.76B | ||
| AMGN | AMGEN INC | 13.37 | 149.21B | ||
| GILD | GILEAD SCIENCES INC | 13.85 | 133.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.63B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.79 | 56.39B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.38B | ||
| ARGX | ARGENX SE - ADR | 98.79 | 34.69B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.82 | 28.86B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
| NTRA | NATERA INC | N/A | 23.47B | ||
| INSM | INSMED INC | N/A | 19.29B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About ONCO
Company Profile
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. The company is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
Company Info
ONCONETIX INC
201 E. Fifth Street, Suite 1900
Cincinnati OHIO US
Employees: 12
Phone: 15136204101
ONCONETIX INC / ONCO FAQ
What is the stock price of ONCONETIX INC today?
The current stock price of ONCO is 4.12 USD. The price increased by 2.23% in the last trading session.
What is the ticker symbol for ONCONETIX INC stock?
The exchange symbol of ONCONETIX INC is ONCO and it is listed on the Nasdaq exchange.
On which exchange is ONCO stock listed?
ONCO stock is listed on the Nasdaq exchange.
What is ONCONETIX INC worth?
ONCONETIX INC (ONCO) has a market capitalization of 182.76M USD. This makes ONCO a Micro Cap stock.
How many employees does ONCONETIX INC have?
ONCONETIX INC (ONCO) currently has 12 employees.
What are the support and resistance levels for ONCONETIX INC (ONCO) stock?
ONCONETIX INC (ONCO) has a resistance level at 6.29. Check the full technical report for a detailed analysis of ONCO support and resistance levels.
Should I buy ONCONETIX INC (ONCO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONCO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONCO, evaluating the profitability, health, valuation and growth aspects
- ONCONETIX INC (ONCO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ONCONETIX INC (ONCO) Sales and EPS estimates to see what analysts future expectations are.
- ONCONETIX INC (ONCO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ONCONETIX INC (ONCO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ONCONETIX INC (ONCO) Stock Chart to make your own analysis
- ONCONETIX INC (ONCO) Latest news and press-releases to stay up to date.
Does ONCONETIX INC (ONCO) stock pay dividends?
ONCO does not pay a dividend.
When does ONCONETIX INC (ONCO) report earnings?
ONCONETIX INC (ONCO) will report earnings on 2025-08-27.
What is the Price/Earnings (PE) ratio of ONCONETIX INC (ONCO)?
ONCONETIX INC (ONCO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-52.26).
ONCO Technical Analysis
ONCO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ONCO. ONCO has a bad profitability rating. Also its financial health evaluation is rather negative.
ONCO Financial Highlights
Over the last trailing twelve months ONCO reported a non-GAAP Earnings per Share(EPS) of -52.26. The EPS decreased by -9.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -208.99% | ||
| ROE | -612.84% | ||
| Debt/Equity | 0.97 |
ONCO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ONCO. The Buy consensus is the average rating of analysts ratings from 6 analysts.